US Patent
US10730876 — Synthesis of a compound that modulates kinases
Composition of Matter · Assigned to Daiichi Sankyo Co Ltd · Expires 2036-05-05 · 10y remaining
Vulnerability score
4/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects processes for preparing a compound, Pexidartinib hydrochloride, that modulates kinases c-Kit, c-Fms, and Flt3.
USPTO Abstract
The present disclosure provides processes for the preparation of a compound of formula I: or a salt thereof, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.